Addendum

Nintedanib (interstitial lung disease) - Addendum to Commission A20-71

Report documents

Indication:

Adults with chronic progressive fibrosing interstitial lung diseases other than SSc-ILD or IPF

Result of dossier assessment:

Still indication of minor added benefit

2021-02-04: A G-BA decision was published

Project no.: A20-124
Commission: Commission awarded on 22.12.2020 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Airways and respiratory system
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.